NEW YORK (GenomeWeb News) – The David H. Murdock Research Institute today announced it has acquired the Immune Tolerance Institute for an undisclosed amount.
The acquisition enhances DHMRI's capabilities to discover novel immunomodulatory therapies and corresponding biomarkers for translation into clinical practice, DHMRI said.
"The acquisition of ITI will allow us to extend the DMHRI's capabilities even further into the pre-clinical and clinical settings, and thus provide increasingly integrated solutions from discovery into development, ultimately improving the health of patients and consumers alike," DMHRI President Mike Luther said in a statement.
Based in Kannapolis, NC, DHMRI provides genomic, proteomic, cellular, and bioinformatics technology platforms to academic and industry partners. ITI is a non-profit based in Menlo Park, Calif., and develops treatments for immune system-related diseases.
Last year, DHMRI and ITI established a research center to speed up discovery and development of treatments for such conditions.